PANACEABIONSEPanacea Biotec Limited· PharmaceuticalsMediumPositive
Announced Tue, 7 Apr · 12:20 IST

Panacea Biotec Limited has informed the Exchange about the receipt of rectified Assessment Order dated 06.04.2026 from the Deputy Commissioner of Income Tax. Under this order, the errors have been corrected, and the Company's tax liability for AY 2016-17 has been determined as Nil.

Regulatory & Legal View source PDF

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.4%1-day move
₹322.00
prior close
₹321.45
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.5+0.1+0.4+3.4+0.3+1.3+3.3+7.9+11.7+14.6+25.9+71.7+66.5
Up moveDown movePending
AI summary

Panacea Biotec received a rectified Assessment Order dated April 6, 2026 from the Deputy Commissioner of Income Tax (DCIT), New Delhi. This order corrects an earlier demand order from March 1, 2026 that had raised a tax demand of approximately ₹10.23 crore for Assessment Year 2016-17. The errors corrected were double addition of disallowances and omission of set-off for brought-forward losses. Following the rectification, the company's tax liability for AY 2016-17 has been determined as Nil. The company does not foresee any adverse impact on its financial, operational, or other activities from this order.

Likely market impact

Positive development for shareholders as the ₹10.23 crore tax demand has been completely nullified, removing any financial liability related to Assessment Year 2016-17.